"Intestinal Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the INTESTINES.
| Descriptor ID |
D007414
|
| MeSH Number(s) |
C04.588.274.476.411 C06.301.371.411 C06.405.249.411 C06.405.469.491
|
| Concept/Terms |
Intestinal Neoplasms- Intestinal Neoplasms
- Intestinal Neoplasm
- Neoplasm, Intestinal
- Neoplasms, Intestinal
- Intestines Neoplasms
- Intestines Neoplasm
- Neoplasm, Intestines
- Neoplasms, Intestines
Cancer of Intestines- Cancer of Intestines
- Intestines Cancers
- Cancer of the Intestines
- Intestines Cancer
- Cancer, Intestines
- Cancers, Intestines
- Intestinal Cancer
- Cancer, Intestinal
- Cancers, Intestinal
- Intestinal Cancers
|
Below are MeSH descriptors whose meaning is more general than "Intestinal Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Intestinal Neoplasms".
This graph shows the total number of publications written about "Intestinal Neoplasms" by people in this website by year, and whether "Intestinal Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 0 | 4 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 4 | 3 | 7 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intestinal Neoplasms" by people in Profiles.
-
The Genetics and Screening of Gastroenteropancreatic Neuroendocrine Tumors and Adrenal Tumors. Surg Clin North Am. 2026 Aug; 106(4):555-569.
-
Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking. Surgery. 2026 Jan; 189:109762.
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.
-
Surgical and oncologic outcomes for liver resections of cystic neuroendocrine tumor liver metastasis. Eur J Surg Oncol. 2025 01; 51(1):109464.
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 11 01; 31(11).
-
Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients. J Nucl Med. 2024 10 01; 65(10):1584-1590.
-
Clinicopathologic and Molecular Characterization of Inflammatory Bowel Disease-Associated Neuroendocrine Carcinomas and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Mod Pathol. 2024 10; 37(10):100566.
-
Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma. Arch Pathol Lab Med. 2024 06 01; 148(6):728-734.
-
Primary Tumor Resection and Its Implications in the Modern Treatment Era of Metastatic Small Bowel Neuroendocrine Tumors : Editorial on: "Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors". Ann Surg Oncol. 2024 Apr; 31(4):2187-2189.